For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How has the spinal muscular atrophy grown historically, and what trends indicate future expansion?
The spinal muscular atrophy market size has grown rapidly in recent years. It will grow from $3.53 billion in 2024 to $4.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to increased diagnosis and early detection, increasing prevalence of rare genetic disease, improved healthcare infrastructure, government and regulatory support, and increase in unmet healthcare needs.
The spinal muscular atrophy market size is expected to see rapid growth in the next few years. It will grow to $6.59 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increased awareness and diagnosis, expanding treatment access, increased healthcare investments in rare diseases, a favorable regulatory environment, and growing healthcare expenditure. Major trends in the forecast period include advancements in oral therapies, adoption of gene therapy, technological advancements in drug delivery systems, integration of artificial intelligence in SMA treatment development, and gene editing technologies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp
Which key factors are driving the expansion of the spinal muscular atrophy industry?
The rising prevalence of rare genetic diseases is expected to propel the growth of the spinal muscular atrophy market going forward. Rare genetic diseases are disorders caused by mutations in genes that affect a small percentage of the population, often resulting in severe, chronic health problems. The rising prevalence of rare genetic diseases can be attributed to improved diagnostic technologies, increased awareness, and better access to genetic testing, leading to more cases being identified and reported. Spinal muscular atrophy (SMA) is a rare genetic disorder that exemplifies the challenges and opportunities in understanding inherited diseases. It highlights the importance of advancing research into genetic conditions. For instance, in July 2023, according to a report published by the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. Therefore, the rising prevalence of rare genetic diseases will drive the growth of the spinal muscular atrophy market.
How is the spinal muscular atrophy market segmented by product, application, and end-user?
The spinal muscular atrophy market covered in this report is segmented –
1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)
2) By Age: Pediatric, Adults
3) By Treatment: Drug Therapy, Gene Therapy
4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy
Subsegments:
1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA
2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA
3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA
4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report
Which major trends are influencing the growth of the spinal muscular atrophy industry?
Major companies operating in the spinal muscular atrophy market are developing innovative products, such as dry syrup, to improve medication adherence and ease of administration for pediatric and other patient groups with swallowing difficulties. Dry syrup is a powdered medication that is reconstituted with water before use, commonly prescribed for children and patients who have difficulty swallowing tablets or capsules. For instance, in September 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced regulatory approval from Japan’s Ministry of Health, Labour and Welfare for an expanded indication of its drug Evrysdi (risdiplam). The approval allows its use in pre-symptomatic spinal muscular atrophy (SMA) and extends dosing to infants under two months old. This milestone is crucial as it enables treatment initiation before symptoms appear, potentially enhancing therapeutic outcomes for affected infants. The decision was supported by data from the RAINBOWFISH study, which assessed Evrysdi’s safety and efficacy in infants diagnosed with SMA but not yet symptomatic. Findings showed that treated infants achieved developmental milestones, such as unsupported sitting and improved motor skills, by 12 months, underscoring the drug’s potential to transform the disease’s progression when administered early.
Which leading companies are dominating the spinal muscular atrophy market landscape?
Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd.
Which geographic areas are expected to offer the highest growth opportunities in thespinal muscular atrophy market?
North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Spinal Muscular Atrophy Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965
Need Customized Data On Spinal Muscular Atrophy Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
